Being both a Trop-2 directed antibody and topoisomerase inhibitor drug conjugate, SG was classified as a first-in-class-medication and is EMA and FDA-approved for the second/third-line treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer (regimen (10 mg/kg) on days 1 and 8 of 21-day cycles). Here, TACSTD2 is linked to triple-negative breast carcinoma.